Press Release

BOSTON HARBOR ANGELS SHAPING THE FUTURE ONE DEAL AT A TIME

Boston, MA — Boston Harbor Angels, a leading angel investing group founded in 2005, is funding some of the most exciting startups with the intention of making the world a better place. While launching the hashtag #investingforabetterworld, BHA members have invested in industries covering a wide range, from cloud storage to stroke treatment to canned wine and disinfectants.

“Our members are seasoned professionals and investors backing some of the best startups”, says Ziad Moukheiber, President of Boston Harbor Angels. “We […]

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of the Company’s Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004, based upon technology originally licensed from The University of Texas Health Science Center at San Antonio, to address the unmet need for a drug that can reduce injury to the brain resulting from stroke, […]

Boston Harbor Angels Brings Equity Venture Partners as New Sponsor

Boston Harbor Angels, one of the top three elite angels groups in the US, is pleased to announce that Equity Venture Partners has joined as a new sponsor.
About Equity Venture Partners
Equity Venture Partners (www.equityvp.com) provides fee simple ownership in Class A & B commercial real estate investment opportunities nationwide to accredited investors with a focus on attaining the greatest risk-adjusted rate of return. We act as the General Partner on all EVP investments and unlike many other firms that […]

Boston Harbor Angels Awards Portfolio Companies at Annual Meeting

Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting.
Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ
Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc.
IT Startup of the Year Award: Wasabi
The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi.
The group also honored Mic […]

Boston Harbor Angels Sponsors Babson’s Summer Venture Showcase

Boston Harbor Angels, one of the top three elite angels groups in the US, is proud to sponsor Babson College’s Summer Venture Showcase. This Babson signature event will be hosted at The Federal Reserve Bank of Boston on Thursday, July 27, 2017.
The summer accelerator of the Arthur M. Blank Center for Entrepreneurship, the Summer Venture Program is a 10-week intensive experience designed to accelerate the development of student entrepreneurial ventures. The program supports the most promising graduate and undergraduate […]

Boston Harbor Angels Hosts Gavea Angels of Brazil

Boston Harbor Angels, one of the top three elite angels groups in the US, will be hosting Brazilian angel group Gavea Angels on Thursday, April 6, 2017. Gavea Angels, a leading Brazilian angel investment group, has organized a “Investor’s Week in Boston” to promote and establish connections between the angel communities in Brazil and the US. In addition to the Boston Harbor Angels, Gavea Angels will also visit universities such as Harvard and MIT, the Cambridge Innovation Center and […]

Boston Harbor Angels Bet on New Frontier in Neuroscience

Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson’s Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders […]